-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, Perspective Therapeutics Says Bamzireotide Delivers 37% ORR In All 68 Treated NET Patients, 91% Disease Control, Median Follow-Up Up To 128 Weeks; Grade 3 TEAEs In 29%, No Grade 4 Or 5 Events

Benzinga·11/06/2026 06:10:02
Diffusion vocale
  • Additional analyses presented at NANETS 2026 Multidisciplinary NET Medical Symposium support prior findings of durable ongoing disease control and encouraging responses in all three cohorts across multiple patient populations
  • Preliminary evidence of more robust anti-tumor activity and durable responses in GEP-NET patients whose target lesions all express SSTR2+ supports focusing on this population
  • Bamzireotide continues to be well-tolerated
  • Targeting End-of-Phase 2 meeting in 1Q 2027